Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

13. September 2022 08:02 ET | Quelle: Novome Biotechnologies, Inc.

Novome Biotechnologies Raises $43.5 Million Series B Financing to Advance its Pipeline of Therapeutically Engineered Microbes

- Funding supports ongoing Phase 2a clinical trial in patients with enteric hyperoxaluria, and pipeline of GEMMs candidates for inflammatory bowel disease - - Financing includes new investors led by...
30. Juni 2021 09:00 ET | Quelle: Novome Biotechnologies, Inc.

Novome Biotechnologies Initiates Phase 1/2a Study to Evaluate Therapeutically Engineered Bacteria for the Treatment of Enteric Hyperoxaluria

- NOV-001 is the first therapeutically engineered colonizing gut bacteria to be evaluated in humans - - Phase 1 results anticipated in 2021 and Phase 2a preliminary efficacy results in 2022 - SOUTH...
22. Juni 2021 08:00 ET | Quelle: Novome Biotechnologies, Inc.

Novome Biotechnologies Appoints Dr. Lachy McLean as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Novome Biotechnologies, Inc., a biotechnology company engineering first-in-class, living medicines for chronic diseases, today...
26. Mai 2021 10:00 ET | Quelle: Novome Biotechnologies, Inc.

Novome Biotechnologies Appoints Dr. David N. Cook and Zachary Hornby to its Board of Directors

SOUTH SAN FRANCISCO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Novome Biotechnologies, Inc., a biotechnology company engineering first-in-class, living medicines for chronic diseases, today announced...